Skip to content
Screener

Operating Income at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.25B+8.3%
Cytokinetics logo
CytokineticsCYTK
-$179.17M-60.7%
Mannkind logo
MannkindMNKD
-$350K-107%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
-$45.34M-2.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.78M+124%

Segments

By segment

See full
Reportable Segment-$26.54M-810%

Other financials

Income statement

See full
Revenue$692.0K-97.6%
Gross profit$653.0K-97.7%
Net income-$31.8M-1,077%
EPS (diluted)-$0.07-800%

Balance sheet

See full
Cash & equivalents$40.9M-18.7%
Total debt$59.2M-3.6%
Total equity$174.5M+34.8%
Total assets$250.1M+10.9%

Cash flow

See full
Operating cash flow-$9.2M
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$1.05B+151%
Enterprise value$1.07B+149%
P/S25.3×+18.1×

Profitability

See full
Gross margin99.1%0.0pp
Operating margin-131.4%-34.2pp
Net margin-147.4%-32.8pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-40.2%-11.2pp
Debt / equity0.3×-0.1×
Current ratio13.4×+9.2×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001062822-26-000117
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively17,44315,74730,19931,050
Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively9,7509,35018,98420,958
Total operating expenses27,23225,13049,33052,071
(Loss) income from operations(26,540)3,736(27,536)(21,943)
Interest and other expense(2,609)(2,318)(4,199)(4,153)
Interest and other income1,7231,8343,2664,053
Loss on early extinguishment of debt(4,349)(4,349)
Net (loss) income$(31,775)$3,252$(32,818)$(22,043)

Item 1. Financial Statements

FAQ

What is Lexicon Pharmaceuticals's operating income?
Lexicon Pharmaceuticals (LXRX) reported operating income of -$26.54M in Q2 2026.
How has Lexicon Pharmaceuticals's operating income changed year-over-year?
Lexicon Pharmaceuticals's operating income decreased by 810.4% year-over-year, from $3.74M to -$26.54M.
What is the long-term trend for Lexicon Pharmaceuticals's operating income?
Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's operating income has grown at a -13.4% compound annual growth rate (CAGR), from -$87.09M to -$48.91M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Lexicon Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude